CHILD UNDER 12 YEARS, NOT RECOMMENDED.
OMALIZUMAB 150 TO 375 MG IS ADMINISTERED SC EVERY 2 OR 4 WEEKS. BECAUSE THE SOLUTION IS SLIGHTLY VISCOUS, THE INJECTION MAY TAKE 5-10 SECONDS TO ADMINISTER. DOSES (MG) AND DOSING FREQUENCY ARE DETERMINED BY SERUM TOTAL IGE LEVEL (IU/ML), MEASURED BEFORE THE START OF TREATMENT, AND BODY WEIGHT (KG). DOSES OF MORE THAN 150 MG ARE DIVIDED AMONG MORE THAN ONE INJECTION SITE TO LIMIT INJECTIONS TO NOT MORE THAN 150 MG PER SITE.
THE NEED FOR CONTINUED THERAPY SHOULD BE PERIODICALLY REASSESSED BASED UPON THE PATIENT'S DISEASE SEVERITY AND LEVEL OF ASTHMA CONTROL.
ADMINISTRATION EVERY 4 WEEKS:
PRE-TREATMENT BODY WEIGHT (KG) :
SERUM IGE(IU/ML)
30-60 > 60-70 >70-90 >90-150
= 30-100 150 150 150 300
> 100-200 300 300 300
> 200-300 300 SEE TABLE BELOW
> 300-400
> 400-500
> 500-600
ADMINISTRATION EVERY 2 WEEKS:
PRE-TREATMENT BODY WEIGHT (KG)
SERUM IGE(IU/ML)
30-60 >60-70 >70-90 >90-150
= 30-100 SEE UPPER TABLE
> 100-200 225
> 200-300 225 225 300
> 300-400 225 225 300
> 400-500 300 300 375
> 500-600 300 375 DONOTDOSE
> 600-700 375
DOSE DETERMINATION AFTER TREATMENT INTERRUPTIONS LASTING LESS THAN 1 YEAR SHOULD BE BASED ON SERUM IGE LEVELS OBTAINED AT THE INITIAL DOSE DETERMINATION. TOTAL SERUM IGE LEVELS MAY BE RE-TESTED FOR DOSE DETERMINATION IF TREATMENT WITH XOLAIR HAS BEEN INTERRUPTED FOR ONE YEAR OR MORE.
NUMBER OF INJECTIONS AND TOTAL INJECTION VOLUMES FOR ASTHMA
DOSE
(MG) NO. OF INJECTIONS TOTAL VOL. INJECTED
150 1 1.2 ML
225 2 1.8 ML
300 2 2.4 ML
375 3 3.0 ML